All In Biotech

Drug Trial Radar · NCT03600233

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

34

Actual

Start

Dec 15, 2018

Primary completion

Sep 30, 2024

Study completion Mar 31, 2026

Sponsor

Lead sponsor
TaiRx, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.

Conditions

  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumor
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Neoplasm
  • Neuroendocrine Carcinoma

Interventions

  • CVM-1118Drug

    Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose). Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to progression-free survival (PFS)Time frame: 12 months after the last patient enrolled

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Chang Gung Memorial Hospital, KaoHsiung

    Kaohsiung City, Taiwan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, Taiwan

  • New Taipei Municipal TuCheng Hospital

    New Taipei City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital, LinKou

    Taoyuan City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.